Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SCHAUMBURG, Ill., Feb. 25, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Frank Harmon as Executive Vice President, Global Operations. In this newly created role, Mr. Harmon will oversee Sagent's Global Operations including Product Development, R&D, Manufacturing, Supply Chain, Regulatory and Global Alliance Management, with oversight support of Quality Assurance. Mr. Harmon will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our “Triple E” strategy which is focused on accelerating our growth and enhancing our operational performance,” said Mr. Oberman. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation.”
Mr. Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as Vice President, Operations of Nesher Pharmaceuticals (“Nesher”), a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products. Prior to joining Nesher, Mr. Harmon served as Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, where he was responsible for managing a global network of parenteral manufacturing facilities and its global supply chain including supply from some of Sagent’s current partners. He earned an MBA degree from St. Louis University and holds a bachelor's degree in Biology and Chemistry from Western Kentucky University.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605
